Transgenic approaches used to investigate AD rely on the ectopic expression of the mutated human genes, such as APP/PS1 and APP/Tau, that drive fAD but are not representative of the underlying pathology of sAD, which is more prevalent in the population (Borchelt et al., 1997; Lewis et al., 2001). The gene discussed is APP; the disease is familial Alzheimer disease.